EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects
Non-small cell lung cancer (NSCLC) tumours with certain mutations in the epidermal growth
factor receptor (EGFR) tyrosine kinase have been termed 'oncogene addicted'to reflect their …
factor receptor (EGFR) tyrosine kinase have been termed 'oncogene addicted'to reflect their …
[HTML][HTML] Advances on EGFR mutation for lung cancer
G Metro, L Crinò - Translational lung cancer research, 2012 - ncbi.nlm.nih.gov
Patients with advanced non-small-cell lung cancer (NSCLC) and somatic activating
mutations of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) …
mutations of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) …
[HTML][HTML] Navigating the “no man's land” of TKI-failed EGFR-mutated non–small cell lung cancer (NSCLC): a review
B Oronsky, P Ma, TR Reid, P Cabrales, M Lybeck… - Neoplasia, 2018 - Elsevier
As the leading cause of cancer-related mortality, lung cancer is a worldwide health issue
that is overwhelmingly caused by smoking. However, a substantial minority (~ 25%) of …
that is overwhelmingly caused by smoking. However, a substantial minority (~ 25%) of …
First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology
M Sebastian, A Schmittel, M Reck - European respiratory …, 2014 - Eur Respiratory Soc
Recent advances in understanding the mechanisms of nonsmall cell lung cancer (NSCLC)
has led to the development of targeted treatments, including the reversible epidermal growth …
has led to the development of targeted treatments, including the reversible epidermal growth …
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
C Tomasello, C Baldessari, M Napolitano, G Orsi… - Critical reviews in …, 2018 - Elsevier
In the last few years, the development of targeted therapies for non-small cell lung cancer
(NSCLC) expressing oncogenic driver mutations (eg EGFR) has changed the clinical …
(NSCLC) expressing oncogenic driver mutations (eg EGFR) has changed the clinical …
Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures
DH Lee - Pharmacology & therapeutics, 2017 - Elsevier
The discovery of epidermal growth factor receptor (EGFR) activating mutations in non-small
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor …
KSH Nguyen, S Kobayashi, DB Costa - Clinical lung cancer, 2009 - Elsevier
Abstract Most advanced Non–Small-cell lung cancers (NSCLCs) with activating epidermal
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …
[HTML][HTML] Epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC)
C O'Leary, H Gasper, KB Sahin, M Tang, A Kulasinghe… - Pharmaceuticals, 2020 - mdpi.com
Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic drivers
in non-small-cell lung cancer (NSCLC). Significant developments have taken place which …
in non-small-cell lung cancer (NSCLC). Significant developments have taken place which …
Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma
J Cadranel, AM Ruppert, M Beau-Faller… - Critical reviews in …, 2013 - Elsevier
Activating mutation in exons 19 or 21 of epidermal growth factor receptor (EGFR) in non-
small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine …
small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine …
Chemotherapy with erlotinib or chemotherapy alone in advanced non‐small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors
SB Goldberg, GR Oxnard, S Digumarthy… - The …, 2013 - academic.oup.com
Purpose. Epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer has
an oncogene‐addicted biology that confers sensitivity to EGFR tyrosine kinase inhibitors …
an oncogene‐addicted biology that confers sensitivity to EGFR tyrosine kinase inhibitors …